Poll Results
January 2019 Question of the Month
Are there more challenges with the new lower priced Repatha NDC compared with the higher priced NDC?
Yes: 57.1%
No: 42.9%
Do you think brand manufacturer’s strategy to introduce a lower priced brand NDC of an existing product is going to expand in 2019?
Yes: 85.7%
No: 14.3%
December 2018 Question of the Month
Will there be a(n) ______ number of pharmaceutical product price changes in 2019 compared to 2018?
Increased: 63.64%
Decreased: 0.00%
Similar: 36.36%
November 2018 Question of the Month
Do you believe there are sufficient treatment options for HIV to warrant formulary exclusions?
Yes: 75%
No: 25%
Do you believe there are sufficient treatment options for Hemophilia to warrant formulary exclusions?
Yes: 71%
No: 29%
Do you believe there are sufficient treatment options for Hereditary Angioedema to warrant formulary exclusions?
Yes: 17%
No: 83%
October 2018 Question of the Month
How will state regulation and licensure of PBMs impact retail pharmacies? (select all that apply)
Improve pharmacy reimbursement rates: 5.88%
Add transparency to Rx reimbursement: 35.29%
Reduce PBM conflict of interests: 17.65%
Eliminate retrospective financial clawbacks: 17.65%
No impact: 11.76%
Reduce pharmacy reimbursement rates: 11.76%
September 2018 Question of the Month
How will the addition of step therapy on Medicare Part B drugs impact biosimilars?
Increase use of biosimilars: 54.55%
No Change: 36.36%
Decrease biosimilar use: 9.09%
August 2018 Question of the Month
Will deeply discounted WAC prices (list price) for biosimilars and specialty generics influence uptake?
Yes: 28.6%
Some impact: 57.1%
No: 14.3%
July 2018 Question of the Month
What is your opinion on pharmacists being allowed to refuse to dispense a prescription for ethical reasons?
Agree: 12.5%
Agree, if they can find another reasonable option for the patient: 56.25%
Disagree: 25%
Indifferent: 6.25%
June 2018 Question of the Month
Do you feel that disclosing the list price of prescription drugs during DTC ads will decrease patient demand for certain products?
Yes: 14.3%
No: 85.7%
May 2018 Question of the Month
Are pharmacists’ licenses at risk when dispensing medical marijuana, a DEA Schedule I substance?
Yes: 66.7%
No: 33.3%
April 2018 Question of the Month
Which of these do you expect to create the biggest buzz in 2018?
Biosimilar availability: 11.0%
Clawbacks or DIR fees: 27.8%
Copay cards for generic drugs: 5.6%
Mergers in healthcare: 50.0%
Outcomes-based agreements: 5.6%
Contact
968 Perry Highway
Pittsburgh, PA 15237
Get Directions »
Phone: (412) 635-4650
Follow/Subscribe:
